SCP
STAB

Sandhill Capital Partners’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Sandhill Capital Partners’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,570
Closed -$2K – 92
2022
Q3 		$2K Hold
13,570
– – ﹤0.01% 82
2022
Q2 		$4K Hold
13,570
– – ﹤0.01% 86
2022
Q1 		$4K Buy
+13,570
New +$14.5K ﹤0.01% 92

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sandhill Capital Partners's STAB Position: Q4 2022 in Review

Sandhill Capital Partners sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q4 2022, closing a stake of 13,570 shares — an estimated $2K sold.

Sandhill Capital Partners first reported a position in STAB in Q1 2022 and held it in 3 quarters. The position peaked at $4K in Q2 2022. 29 funds tracked by Wall St. Rank hold STAB as of Q4 2022.

  • Sandhill Capital Partners reported no remaining Statera Biopharma, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Sandhill Capital Partners sold 13,570 Statera Biopharma, Inc. Common Stock shares in Q4 2022, an estimated $2K.
  • Sandhill Capital Partners first reported a position in Statera Biopharma, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Sandhill Capital Partners's Statera Biopharma, Inc. Common Stock position peaked at $4K in Q2 2022.
  • 29 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q4 2022.

Based on Sandhill Capital Partners's 13F filing for Q4 2022, filed 10 Feb 2023.